Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Opexa Therapeutics

- PMLiVE

Merck’s digital health accelerator expands into Africa

Will run new startup support programme in Nairobi

- PMLiVE

Merck KGaA adds two to its executive board

Appoints Udit Batra and Walter Galinat, while Bernd Reckmann will retire

- PMLiVE

Germany’s Merck triumphs in court battle with US namesake

English court rules Merck & Co breached the firms' naming agreement

- PMLiVE

Syndax teams with Merck/Pfizer on immuno-oncology combo

Oral cancer drug entinostat to test with avelumab

- PMLiVE

Another setback for Teva’s laquinimod in MS

Side effects seen in two late-stage trials but development will continue

- PMLiVE

Merck abandons evofosfamide as two trials fail

Solid tumour candidate underwhelms in phase III studies

- PMLiVE

FDA deems Merck KGaA and Pfizer’s avelumab a breakthrough

Could become first-in-class treatment for Merkel cell carcinoma

- PMLiVE

Merck KGaA and Pfizer move avelumab into late-stage trials

Begin phase III studies of the monoclonal antibody in lung cancer

- PMLiVE

Merck appoints new senior vice president

Laszlo Radvanyi joinsthe firm

Biogen Idec building

Biogen cuts workforce and culls pipeline projects

Attempts to make major cost savings as MS drug sales slow

- PMLiVE

Merck names new CEO and rebrands under one name

New logo and appointment of Stefan Oschmann from next year

- PMLiVE

FDA fast-tracks Merck/Pfizer’s rare skin cancer drug avelumab

Comes a month after drug was given orphan status

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links